Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
In Feb 2026, a Canadian survey found ~3M adults used GLP-1 drugs for weight, diabetes, or heart health, reporting appetite reduction and lifestyle changes, despite cost and coverage barriers.
A survey of Canadian adults conducted in February 2026 finds that about three million people are using GLP-1 drugs like Ozempic or Mounjaro, primarily for weight loss, diabetes, or heart health.
Users report reduced appetite, fewer cravings, smaller portion sizes, and less frequent dining out or alcohol consumption.
Many are buying more fresh foods and spending more on clothing, fitness, and personal care.
Despite high interest, over two million others are deterred by cost and limited insurance coverage, with only 28% fully covered.
Common side effects include nausea and digestive issues, though serious complications are rare.
The findings suggest a significant shift in eating and spending habits driven by these medications.
En febrero de 2026, una encuesta canadiense encontró que ~ 3M adultos usaron medicamentos GLP-1 para el peso, la diabetes o la salud del corazón, reportando reducción del apetito y cambios en el estilo de vida, a pesar de las barreras de costo y cobertura.